AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28138865
Drug: Sensorial training
RxNorm normalized name: SENSORY ORGANS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensorial training of the posterior thigh in addition to neurodevelopmental treatment
Trial: 28138865
Drug: Neurodevelopmental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodevelopmental treatment only (control group)
Trial: 19628934
Drug: Aspirin treatment
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin treatment in the UK‐TIA Trial
Trial: 15529649
Drug: Glycerin formulation
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerin formulation of ototopical 0.3% ciprofloxacin
Trial: 9012900
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) at a low dose of 10 ppm
Trial: 3580158
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (preoperative irradiation followed by radical excision or irradiation alone).
Trial: 27391833
Drug: Fat grafting
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat grafting (mean volume of 4.8 cc per foot)
Trial: 16632233
Drug: 3x daily
RxNorm normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3x daily insulin lispro
Trial: 16632233
Drug: 3x daily
RxNorm normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3x daily lispro mid mixture (MidMix; 50% lispro, 50% protaminated lispro)
Trial: 16632233
Drug: 1x daily
RxNorm normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1x daily insulin glargine
Trial: 16632233
Drug: 3x daily
RxNorm normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3x daily lispro mid mixture (MidMix)
Trial: 30789801
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 1200 mg/day for 8 weeks
Trial: 23591657
Drug: Nonopioid medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonopioid medications
Trial: 27338193
Drug: Carboplatin plus
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin plus paclitaxel doublet chemotherapy
Trial: 27338193
Drug: Monotherapy (vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (vinorelbine or gemcitabine)
Trial: 22716999
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg escitalopram daily for 7 days
Trial: 12324294
Drug: Zinc (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (20 mg/d for infants, 40 mg/d for older children)
Trial: 2590267
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg theophylline administered at 8 a.m.
Trial: 2590267
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg theophylline administered at 8 p.m.
Trial: 2590267
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg theophylline administered at 8 a.m. and 8 p.m.
Trial: 21816079
Drug: Non-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment group
Trial: 29096689
Drug: Rectally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectally administered indomethacin
Trial: 19010927
Drug: Low-dose tamoxifen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tamoxifen (5 mg/daily)
Trial: 26510183
Drug: Patient-Controlled Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-Controlled Intravenous Analgesia (PCIA)
Trial: 23948997
Drug: Standard daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard daily S‐1 administration (80‐120 mg/day depending on BSA; days 1‐28 every 6 weeks for 1 year)
Trial: 23948997
Drug: Alternate-day S‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day S‐1 administration (80‐120 mg/day depending on BSA; alternate days for 15 months)
Trial: 19568216
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) training
Trial: 31483689
Drug: Somatic yoga
RxNorm normalized name: Bos taurus somatic nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatic yoga and meditation (weekly for 8 weeks, with home program)
Trial: 25064681
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of medication and psychosocial intervention
Trial: 22892337
Drug: Mesalamine 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 2.4 g
Trial: 17617807
Drug: Measles vaccine
RxNorm normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles vaccine ROUVAX
Trial: 12848629
Drug: 15-month treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-month treatment
Trial: 23954387
Drug: Oxiplex/AP gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiplex/AP gel (Intercoat)
Trial: 20416952
Drug: Modified Early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Early Treatment of Diabetic Retinopathy Study (ETDRS) macular laser therapy (MLT)
Trial: 18625518
Drug: Cervical injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical injection
Trial: 18625518
Drug: Hysteroscopic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hysteroscopic injection
Trial: 16143698
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose, then 75 mg once daily)
Trial: 11845882
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for heart failure
Trial: 11845882
Drug: Propranolol (additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (additional treatment)
Trial: 2115308
Drug: Metrifonate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate (10 mg/kg, repeated at 4 month intervals)
Trial: 18850387
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (postmenopausal women)
Trial: 14535021
Drug: 654‐2 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 654‐2 injection and 'Gan Xian Tui Huang Recipe'
Trial: 17116834
Drug: Imiquimod treatment
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod treatment
Trial: 17038243
Drug: Standard nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nutrition support + Gln 100 ml/d + rhGH 10 U/d (Group C)
Trial: 17038243
Drug: Standard nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nutrition support + 10% Gln 100 ml/d (Group B)
Trial: 12812018
Drug: Transdermal Nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal Nicotine System (TNS) for 3 weeks
Trial: 12812018
Drug: Transdermal Nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal Nicotine System (TNS) for 6 weeks
Trial: 11157426
Drug: Control drugs
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control drugs (tricyclics/heterocyclics and SSRIs)
Trial: 3299016
Drug: MK-733 (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-733 (low dose: 2.5-10 mg/day)
Trial: 3299016
Drug: MK-733 (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-733 (high dose: 20-80 mg/day)
Trial: 28624696
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of trastuzumab after chemotherapy
Trial: 21705493
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of intravenous iron (III)-hydroxide sucrose
Trial: 16957676
Drug: Estromineral serena
RxNorm normalized name: Serenoa preparation
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estromineral serena (ES) - 1 tablet/day for 24 weeks
Trial: 15077843
Drug: Outpatient substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient substance abuse treatment
Trial: 12573306
Drug: Climodien (estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Climodien (estradiol valerate 2 mg + dienogest 3 mg)
Trial: 11304940
Drug: Climodien (estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Climodien (estradiol valerate 2 mg + dienogest 2 mg)
Trial: 9034258
Drug: 4% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% albumin solution (0.6 g/kg) administered after withdrawing 15 mL/kg of blood over 30 mins in group 2.
Trial: 8509529
Drug: Alternative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative therapy after combination therapy was discontinued
Trial: 30943512
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment of the primary tumour and lymph nodes metastasis
Trial: 30943512
Drug: Non-surgical approaches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical approaches (including radiotherapy and systemic medical treatment)
Trial: 29512061
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiotherapy
Trial: 27019066
Drug: Citalopram infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram infusion
Trial: 16996783
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis combined with pre and postsurgery hyperbaric oxygen (HBO) treatment
Trial: 16199795
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER (75‐225 mg/day)
Trial: 12022898
Drug: Regular coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular coffee (180 mg caffeine in 200 mL beverage)
Trial: 12022898
Drug: Decaffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated coffee (3.6 mg caffeine in 200 mL beverage)
Trial: 8521744
Drug: Teicoplanin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (400 mg once daily)
Trial: 1968308
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg) after 17 h during dopamine infusion
Trial: 26555945
Drug: Mammalian target
RxNorm normalized name: Mammalian target of rapamycin (mTOR) kinase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mammalian target of rapamycin inhibitor-free immunosuppression (group A)
Trial: 17403819
Drug: Drainage, irrigation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drainage, irrigation, and fibrinolytic therapy
Trial: 17403819
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (tapping of cerebrospinal fluid by reservoir)
Trial: 9616309
Drug: Budesonide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (3 x 1 mg/day)
Trial: 2558829
Drug: UFH regimen:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFH regimen: 5,000 IU bolus and 1,500 IU/h infusion
Trial: 8348875
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (100 mg)
Trial: 19236643
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg x kg(‐1) propofol
Trial: 19526159
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg x kg(‐1) metoclopramide
Trial: 18001178
Drug: No ablative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ablative therapy (n = 42)
Trial: 16200556
Drug: Home chemotherapy
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home chemotherapy
Trial: 12151468
Drug: Risperidone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.5 to 3.5 mg per day)
Trial: 9849978
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (concomitant injections of M-M-R II, VARIVAX, and TETRAMUNE)
Trial: 9849978
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (VARIVAX injection sites)
Trial: 805050
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg, 3 times daily)
Trial: 28617807
Drug: Methylprednisolone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 0.5 mg/kg/tpd with β-lactam plus macrolide
Trial: 28617807
Drug: Methylprednisolone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 0.5 mg/kg/tpd with β-lactam plus fluoroquinolone
Trial: 19713654
Drug: Bilateral stellate
RxNorm normalized name: Mastocarpus stellatus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral stellate ganglion block with 8 ml 1% lidocaine solution
Trial: 17908769
Drug: IL6‐174 G/G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL6‐174 G/G genotype
Trial: 17908769
Drug: TNFA promoter
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TNFA promoter genotypes ‐238 G/G and ‐376 G/G, TLR4 299 A/A genotype
Trial: 17908769
Drug: TNFA‐238 G/G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFA‐238 G/G genotype or TNFA‐863 A allele carriage
Trial: 7812483
Drug: Metal subcutaneous
RxNorm normalized name: menthone 1,2-glycerol ketal, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metal subcutaneous needle
Trial: 7812483
Drug: Volume of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume of medication injected per day
Trial: 340140
Drug: Aluminium hydroxide
RxNorm normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminium hydroxide B.P. tablets (500 mg)
Trial: 31080025
Drug: Simple nasal
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple nasal external compression (saline solution)
Trial: 17992378
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment + brief psychological intervention (LSPI)
Trial: 17992378
Drug: Conventional pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pharmacological treatment (CT)
Trial: 17992378
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment + guidance program (OG)
Trial: 11028250
Drug: Rofecoxib 25
RxNorm normalized name: rofecoxib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 25 mg qd
Trial: 10470596
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg tid
Trial: 15338504
Drug: Ibuprofen 800
RxNorm normalized name: ibuprofen 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 800 mg tid
Trial: 11028250
Drug: Sodium naproxen
RxNorm normalized name: Naproxen Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium naproxen 550 mg bid
Trial: 8746167
Drug: radioiodine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radioiodine therapy (aRIT)
Trial: 1326349
Drug: Rifabutin (B)
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin (B) daily
Trial: 1326349
Drug: Rifampicin (R)
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifampicin (R) daily
Trial: 2185303
Drug: Milnacipran 100
RxNorm normalized name: milnacipran 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran 100 mg/d
Trial: 22265923
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 50mg every day for 5 days (days 3-7 of cycle)
Trial: 7657280
Drug: Ursodiol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodiol (10 to 12 mg/kg at bedtime for 2 years)
Trial: 31654328
Drug: Upadacitinib extended-release
RxNorm normalized name: upadacitinib Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib extended-release formulations (four different formulations)
Trial: 31654328
Drug: Upadacitinib immediate-release
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib immediate-release capsule formulation
Trial: 31654328
Drug: External validation
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External validation formulation
Trial: 25795697
Drug: Preferring medications
RxNorm normalized name: Proferrin
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preferring medications
Trial: 23632142
Drug: Whole-home exercise
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-home exercise intervention (training for care home staff and twice-weekly physiotherapist-led exercise group)
Trial: 21277231
Drug: Levetiracetam 1500
RxNorm normalized name: levetiracetam 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam 1500 mg daily divided in two doses for 12 weeks
Trial: 8452171
Drug: Fleroxacin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin, 400 mg intravenously once a day
Trial: 24040947
Drug: A100 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A100 1.8 mL
Trial: 24040947
Drug: A100 3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A100 3.6 mL
Trial: 1957404
Drug: Human serum
RxNorm normalized name: Human serum albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human serum albumin (hSA) 200 mg/ml
Trial: 31594736
Drug: Single intravesical
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravesical instillation (SIC) with epirubicin 50 mg
Trial: 31594736
Drug: Maintenance intravesical
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance intravesical chemotherapy (MIC) once weekly for 6 weeks plus once monthly for 1 year
Trial: 27785737
Drug: Entospletinib (25-1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entospletinib (25-1200 mg; fasted) as single or twice-daily oral doses for 7 days
Trial: 27785737
Drug: Entospletinib (≥600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entospletinib (≥600 mg twice daily)
Trial: 29806665
Drug: 6 mm
RxNorm normalized name: I-Port, 6 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mm long implants
Trial: 21742400
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT), administered daily for a total of 20 treatments.
Trial: 10430112
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg celecoxib twice a day
Trial: 16772765
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg acetazolamide twice a day
Trial: 11904978
Drug: rhuMAb‐E25 (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhuMAb‐E25 (recombinant humanized monoclonal anti‐IgE antibody)
Trial: 9818888
Drug: Antimigraine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimigraine therapy
Trial: 606784
Drug: Split-product vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-product vaccines
Trial: 606784
Drug: Whole-virus vaccines
RxNorm normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-virus vaccines
Trial: 26304663
Drug: CABG plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CABG plus medical therapy
Trial: 7769367
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic hormone (ANH) at medium dose (1.8 pmol/kg/min)
Trial: 30830974
Drug: MDT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDT treatment allocation agreement
Trial: 30830974
Drug: MDT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDT treatment allocation agreement (Krippendorff's α)